Juvia Group Research
Overview
Juvia Group is a Boston-based biotech venture firm founded in 2026 by three co-founding Managing Directors: Stefan Vitorovic, Sujal Shah and Jakob Loven. The firm's stated mission is to accelerate the formation and funding of breakthroughs in life sciences for the benefit of patients and investors. It describes itself as a generational investing firm built by seasoned investors, operators and entrepreneurs, and says its team has supported more than 25 FDA-approved therapeutics, 20 IPOs, raised over $15 billion in capital and achieved eight multi-billion-dollar M&A exits. Those figures describe the founders' prior careers, not Juvia's own track record, since the firm is only months old.
Investment Thesis
Juvia backs teams pursuing bold science to make meaningful medicines. Its public approach rests on access (decades-old relationships with biomedical innovators), analysis (a collaborative, rigorous process to build conviction), action (operating experience and follow-through), alignment (values and conduct matching investor interests) and patient impact. A LinkedIn post from a team member describes Juvia as a new life sciences venture fund investing in companies developing new medicines across therapeutic areas, modalities and stages. No explicit anti-thesis is published.
Stage Focus
The firm says it invests across stages. Its two disclosed deals are large, later-stage private rounds: a $135M Series B in Soufflé Therapeutics (Juvia led) and a $350M financing in Dren Bio (Juvia co-led with Lightspeed Venture Partners). This suggests a bias toward growth-stage biotech rounds in its first months, but the firm has not published a stage mandate, so early-stage preferences are not confirmed.
Check Size
Not disclosed. Juvia I, L.P. filed a Form D with the SEC on 2026-05-15, and a co-invest vehicle, Juvia I Coinvest A, L.P., filed a Form D in July 2026 reporting about $13M sold. Fund size and typical check size are not published on the website.
Lead Tendency
Juvia leads or co-leads. It led Soufflé's oversubscribed Series B and co-led Dren Bio's $350M financing alongside Lightspeed.
Recent Activity
- October 2026: Led Soufflé Therapeutics' $135M Series B (announced 2026-10-13). The round included TCG Crossover, BB Biotech, Fidelity, Balyasny and existing investors such as ARCH, Bessemer, Amgen Ventures and Temasek.
- October 2026: Co-led Dren Bio's $350M financing (announced 2026-10-28) with Lightspeed, to advance dibotatug toward commercialization.
- May 2026: Juvia I, L.P. Form D filed with the SEC.
The fund is in active deployment.
Portfolio
The website's portfolio section names two companies. Soufflé Therapeutics is an RNA therapeutics company with a receptor-mediated delivery engine (REMEDY) targeting FSHD, heart failure, and muscle and metabolic disorders. Dren Bio develops first-in-class therapeutics for cancer, autoimmune and other serious diseases, led by dibotatug. The "Decades of turning ideas into impact" section lists approved drugs (Vitrakvi, Keytruda, Welireg, Livdelzi, Leqembi, Bavencio and others) that team members worked on at prior employers or funds. These are not Juvia portfolio companies and are excluded.
Team
- Stefan Vitorovic, Co-Founder and Managing Director. Founding investor in Peloton Therapeutics, Praxis Precision Medicines and Decibel Therapeutics.
- Sujal Shah, Co-Founder and Managing Director. Former CEO/CFO of CymaBay Therapeutics (Livdelzi); sits on Soufflé's board.
- Jakob Loven, Co-Founder and Managing Director. Investor and founding team member at Revolution Medicines and Relay Therapeutics.
- Mazdak Abulnaga, Head of AI; Harry Won, Senior Associate; Dylan Neel, Analyst; Aditya Raj, Junior Analyst; Luka Tomasevic, Business Fellow.
- Arran Attridge, Head of Communications; Susana Chartier, VP of Finance; Ida Louie, Controller; Jessica Kolowich, Manager of Operations; Edward (Ted) Karns, Senior Advisor.
- Science Partners: Samantha Budd Haeberlein, Keith Flaherty, Nathanael Gray, Chuck McWherter, Mark Murcko, Alise Reicin and Mike Varney.
Decision Process
Not published. The firm is led by three co-founders, which points to a partnership model with a Science Partner network supporting diligence.
Founder Preferences
Exceptional scientific teams working on breakthrough medicines. Soufflé's CEO and Dren Bio's CEO both credit the Juvia partners as hands-on, board-level partners.
Geographic Focus
Boston, Massachusetts headquarters (One International Place). Both disclosed investments are US companies. No explicit geographic restriction is published.
Gaps
Fund size, check size, stage mandate and decision timeline are not public. Crunchbase mislabels the firm as a hospitality investor; the SEC filings and the firm's own site confirm it is a life sciences fund.